Trial Profile
An Open label, Multi-Center, Phase I/II study of vemurafenib in patients with unresectable or Metastatic Melanoma with BRAFV600 Mutation
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 May 2016
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 11 Dec 2014 New source identified and integrated (Japan Pharmaceutical Information Center: JAPIC Clinical Trials Information - JapicCTI-121940).
- 17 Aug 2011 Planned initiation date changed from 1 Jun 2011 to 1 Jun 2012.
- 16 Aug 2011 New trial record